Fred Hutch News ServiceNew nanoparticles make targeted, temporary gene therapy possibleFred Hutch News ServiceScientists seeking a simple and gentle way to provide short-term gene therapy have a new tool: nanoparticles. In a paper published August 30 i… Continue reading
Editas Medicine, Inc. (NASDAQ:EDIT) Closed Significantly Above Its 50 Day Moving AverageModern ReadersCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from … Continue reading
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Traded Much Higher Than Its 50 Day Moving AverageModern ReadersCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR fro… Continue reading
Immunotherapy Drugs Market, Company Analysis and Forecast to 2025Medgadget (blog)Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune re… Continue reading
Immunotherapy Drugs Market, Company Analysis and Forecast to 2025Medgadget (blog)Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune re… Continue reading
News-Medical.netInduced Pluripotent Stem Cells (iPSCs) and Cell ReprogrammingNews-Medical.netStem cells represent a valuable asset as observed in previous sections. Even though these stem cells exist in embryonic and adult tissues, harvesting copious p… Continue reading
FOX43.com |
FDA cracks down on stem cell clinics
FOX43.com Dr. Elliot B. Lander, co-founder of the California Stem Cell Treatment Center, said it was “voluntarily participating” in “studies for late-stage, no-options cancer patients” that had been approved by institutional review boards. The boards are … |
San Francisco Chronicle |
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
Yahoo Finance We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The most advanced therapy candidate … ‘Game-changer’ cancer treatment is focus of Gilead’s $12 billion cell therapy dealSan Francisco Chronicle Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma ClosesLymphoma News Today Gilead’s $11.9 billion purchase of a groundbreaking cancer therapy could drag it into a new debate on pricesWashington Post Fairfield Daily Republic –San Francisco Business Times –Drug Discovery & Development –Zacks Investment Research all 63 news articles » |